Bioworld Technology CO., Ltd.

CysLTR2 (K322) Peptide

Cat No.: BS2614P

Background

Cysteinyl leukotriene (CysLTs) induce intracellular calcium mobilization through the binding of two distinct seven-transmembrane, G protein-coupled receptors, designated CysLT1 Receptor and CysLT2 Receptor, to induce potent bronchoconstriction. Airway smooth muscle and macrophages express both receptor types, and additionally monocytes and eosinophils express CysLT1 Receptor, while cardiac Purkinje cells, adrenal medulla, peripheral blood leukocytes and brain also utilize CysLT2 Receptor. The effects of the CysLT Receptors can be blocked by antagonists, indicating a therapeutic mechanism for the treatment of asthma and allergies.

Swiss-Prot

Q9NS75

Applications

Blocking

Specificity

This peptide can be used with studies using BS2614 CysLTR2 (K322) pAb.

Purification & Purity

Synthetic peptide CysLTR2 (K322). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4℃ short term. Aliquot and store at -20℃ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.
1660 South Highway 100, Suite 500 St. Louis Park,MN 55416,USA. **Email: info@bioworlde.com**
Tel: 6123263284 **Fax: 6122933841**

Bioworld technology, co, Ltd.
No 9, weidi road Qixia District Nanjing, 210046, P, R.China. **Email: info@biogot.com**
Tel: +86-025-68037686 **Fax:+86-025-68035151**